Daiichi Sankyo (OTCMKTS:DSNKY) Releases FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.910-0.910 for the period, compared to the consensus estimate of 1.040. The company issued revenue guidance of $14.5 billion-$14.5 billion, compared to the consensus revenue estimate of $13.4 billion.

Daiichi Sankyo Trading Up 1.4%

Shares of DSNKY opened at $17.29 on Wednesday. Daiichi Sankyo has a 1-year low of $15.56 and a 1-year high of $28.21. The company has a 50-day moving average of $17.79 and a 200 day moving average of $20.25. The firm has a market capitalization of $32.75 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 0.88 and a beta of -0.25. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.69 and a quick ratio of 1.85.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, research analysts expect that Daiichi Sankyo will post 1.26 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Daiichi Sankyo currently has an average rating of “Buy”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.